Multiple Innovative Therapies Including ADCs Receive FDA Breakthrough Therapy Designation

　　【Pharmaceutical Network Product InformationIn the field of pharmaceutical research and development, every major breakthrough brings new hope to patients. Recently, several innovative drugs have successively received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA), a development that offers promising prospects for the treatment of related diseases.
 

Merck (MSD) and Daiichi Sankyo recently announced that their jointly developed investigational antibody-drug conjugate (ADC), raludotatug deruxtecan (R-DXd), has been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA for the treatment of adult patients with platinum-resistant CDH6-positive epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who have received prior treatment with bevacizumab.
 

Data show that Raludotatug deruxtecan is a potential CDH6-targeted DXd antibody-drug conjugate. The granting of this Breakthrough Therapy Designation (BTD) is mainly based on the results of its Phase 1 trial and the data from the ongoing REJOICE-Ovarian01 Phase 2/3 clinical trial. Analysis shows that in patients with advanced ovarian cancer who have undergone multiple lines of treatment, the overall response rate of this drug reached 46%, the disease control rate was as high as 98%, and the median duration of response was 11.2 months. It is reported that this designation was granted based on the positive efficacy and potential demonstrated by raludotatug deruxtecan in early clinical trials.
 

Recently, Ionis also announced that the U.S. FDA has granted Breakthrough Therapy Designation to its investigational antisense oligonucleotide (ASO) therapy ION582 for the treatment of Angelman Syndrome (AS).
 

Data shows that ION582 is an investigational ASO therapy administered via intrathecal injection through lumbar puncture. It aims to suppress the expression of the UBE3A antisense transcript and activate the paternal UBE3A allele to increase UBE3A protein production in patients' brains, offering a potential treatment for Angelman syndrome. This designation is based on the positive results from the Phase 1/2 HALOS study, which demonstrated that patients experienced continuous and positive clinical improvements across all functional assessment areas for AS patients, including communication, cognition, and motor function. Additionally, the drug exhibited good safety and tolerability.
 

Johnson & Johnson recently announced that the U.S. FDA has approved its innovative drug Inlexzo (gemcitabine intravesical drug release system [iDRS]) as a breakthrough therapy for the treatment of adult patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG) and carry carcinoma in situ (CIS), with or without papillary tumors.
 

Inlexzo (TAR-200) is an intravesical drug delivery system designed to achieve sustained local release of gemcitabine in the bladder, maintaining local drug exposure for up to several weeks. The approval of Inlexzo was primarily based on data from the SunRISe-1 single-arm, open-label Phase 2b clinical study. The results showed that 82% of BCG-unresponsive NMIBC patients treated with Inlexzo achieved complete response (CR), meaning no signs of cancer were observed after treatment (95% CI: 72-90). This high response rate demonstrated significant durability, with 51% of patients maintaining complete response for at least one year.
 

In addition, Baili Tianheng recently announced that its wholly-owned subsidiary, SystImmune, Inc., along with its partner Bristol-Myers Squibb, declared that the FDA has granted Breakthrough Therapy Designation to izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations, following failure of prior EGFR-TKI and platinum-based chemotherapy.
 

These innovative drugs have received the FDA's Breakthrough Therapy Designation, which not only recognizes the efforts of the research and development team but also brings new hope to patients worldwide. As these drugs continue to be further developed and clinically applied, they are expected to bring revolutionary changes to the treatment of related diseases, improve patients' quality of life, and extend their lifespan.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.